From Wikipedia, the free encyclopedia
Jump to: navigation, search
SB649868 structure.png
Systematic (IUPAC) name
Clinical data
Legal status
  • Investigational
ATC code None
PubChem CID 25195495
ChemSpider 25069706
Chemical data
Formula C26H24FN3O3S 
Mol. mass 477.549 g/mol (free base)

SB-649,868 is an orexin receptor antagonist in development by GlaxoSmithKline.[1][2] Currently in Phase 2 development, this drug for sleep disorders is one of two such compounds currently in development, the other being Merck & Co's suvorexant.[3]


  1. ^ Renzulli C, Nash M, Wright M, Thomas S, Zamuner S, Pellegatti M, Bettica P, Boyle G (February 2011). "Disposition and metabolism of [14C]SB-649868, an orexin 1 and 2 receptor antagonist, in humans". Drug Metab. Dispos. 39 (2): 215–27. doi:10.1124/dmd.110.035386. PMID 21045199. 
  2. ^ Bettica P, Nucci G, Pyke C, Squassante L, Zamuner S, Ratti E, Gomeni R, Alexander R (August 2012). "Phase I studies on the safety, tolerability, pharmacokinetics and pharmacodynamics of SB-649868, a novel dual orexin receptor antagonist". J. Psychopharmacol. (Oxford) 26 (8): 1058–70. doi:10.1177/0269881111408954. PMID 21730017. 
  3. ^

Further reading[edit]